Navigation Links
Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
Date:12/20/2007

e all over the world. In particular, about 20% to 30% of the U.S. population complains of waking too early several times a week, a symptom of sleep maintenance insomnia (SMI) that is characterized by symptoms that include waking up frequently during the night with difficulty returning to sleep, waking up at early hours, and unrefreshing sleep. The majority of sleep complaints are related to SMI rather than sleep initiation or difficulty in falling asleep. However, there are no drugs currently approved in the U.S. that address only SMI. Furthermore, current sleep medications typically induce sedation and result in significant increases in daytime sleepiness that impairs quality of life in these patients. There is, therefore, a significant need for sleep medications that improve sleep quality without next-day hangover effects.

ABOUT ITI-722

ITI-722 is a highly potent 5HT2A antagonist for the treatment of sleep maintenance insomnia. Preclinical data has shown that ITI-722 is not sedating and should not exhibit next-day hangover effects that are commonly associated with other sleep medications. ITI-722 is expected to have a strong safety profile with no addiction liability. This compound is being evaluated for the treatment of sleep disorders in various patient populations with sleep maintenance problems and in other sleep disorders where staying asleep affects the quality of life, including nocturnal awakenings related to osteoarthritic pain, hot flashes in post-menopausal women and many psychiatric and neurodegenerative diseases.

ABOUT CNSProfile(TM)

The Company has developed a state-of-the-art technology platform, called CNSProfile(TM), that is capable of generating a unique molecular signature for drug compounds. Specifically, CNSProfile(TM) measures the levels of phosphoproteins, proteins chemically linked at specific sites to phosphates. This profile provides the Company with a proprietary and unique window into the intracellular action
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
2. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
3. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
4. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
7. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
8. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
9. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
10. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
11. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  The Partnership to Fight Chronic Disease (PFCD) released a public ... and a new study analyzing the impact of increased cost sharing ... coalition working to educate policy makers and the public on the ... focused on how the Iowa healthcare exchange ...
(Date:1/23/2015)... BETHESDA, Md. , Jan. 23, 2015  Northwest Biotherapeutics, Inc. ... developing DCVax® personalized immune therapies for operable and inoperable solid ... will present at the 7 th Annual Phacilitate Immunotherapy ... NW Bio,s presentation at Phacilitate will take place on January ...
(Date:1/23/2015)... than a third of reproductive-aged women enrolled in Medicaid, and ... a prescription for an opioid pain medication each year during ... Mortality Weekly Report (MMWR). Opioids are typically ... pain.  They are also found in some prescription cough medications. ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... 25, 2011 PDI, Inc. (Nasdaq: ... and commercialization services to health care companies, today announced ... 10 pharmaceutical company has been renewed for an additional ... Shared Sales team beginning in September 2011 through March ...
... 2011 Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN ) ... who has conducted multiple clinical studies of zinc lozenges for the ... Mr. Eby is a pioneer in the development of zinc ... more than 30 years to the study of zinc and is ...
Cached Medicine Technology:PDI Announces Renewal of Engagement for 7th Consecutive Season 2Adeona Appoints George A. Eby to Scientific Advisory Board 2Adeona Appoints George A. Eby to Scientific Advisory Board 3Adeona Appoints George A. Eby to Scientific Advisory Board 4
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
(Date:1/22/2015)... 2015 Four years since the release of their ... with the marriage of Avasa & Matthew Love – the duo ... scheduled for release through White Swan Records on February 24, 2015. ... a sacred path available to all of us to walk out ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
(Date:1/22/2015)... 2015 Lower-Auto-Insurance.com has released a new blog post ... car for reducing the costs of an auto insurance policy ... able to get lower prices for their vehicle insurance policies. The ... in determining policy costs. Because of this, drivers should always ...
(Date:12/26/2014)... The US represents the largest market for CRC across ... estimates that sales of branded therapies were $2.23 billion. The ... incidence of the disease, high drug treatment rate, and higher ... sales of CRC therapies over the forecast period will be ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... to Present September,22-24, 2008, WASHINGTON, Sept. ... medical technology companies have been selected to ... presentations offer a unique,business development and information ... the cardiovascular, dental, diagnostics, imaging,metabolic disease/obesity, neurology, ...
... - U.S. Preventive Medicine, Inc.,( http://www.USPreventiveMedicine.com ), the ... Ron Loeppke, M.D., MPH, as Co-Chairman of,the company,s ... researching,the role of primary, secondary and tertiary prevention ... health and,productivity in the workplace, as well as ...
... 1 in U.S. ... ... Inc. and Orphan Therapeutics, LLC announced today that they have,entered into an ... from Orphan Therapeutics., Orphan Therapeutics has initiated a rolling NDA with ...
... 2 The Diversified Agency Services (DAS),unit ... to the position of,Executive Vice President and ... position Sharon will direct the client-centric and,brand-centric ... a,worldwide multidisciplinary resource of specialist agencies that ...
... Sept. 2 September is Cholesterol,Awareness Month. The ... perceived failures in drug trials, Tim Russert,s sudden,death, ... of dyslipidemia in,children have all led to increased ... views these developments as reinforcing the importance of ...
... finding is ,good news, for postmenopausal women taking ... Contrary to previous study results, the cancer prevention ... of cognitive performance, a new study found. ... to tamoxifen in preventing breast cancer recurrence in ...
Cached Medicine News:Health News:Canadian, German, Israeli, New Zealand, U.K and U.S. Companies Selected to Make Company Presentations at AdvaMed 2008 2Health News:Canadian, German, Israeli, New Zealand, U.K and U.S. Companies Selected to Make Company Presentations at AdvaMed 2008 3Health News:Canadian, German, Israeli, New Zealand, U.K and U.S. Companies Selected to Make Company Presentations at AdvaMed 2008 4Health News:U.S. Preventive Medicine Appoints Ron Loeppke, M.D. as Co-Chairman of Its National Advisory Board 2Health News:U.S. Preventive Medicine Appoints Ron Loeppke, M.D. as Co-Chairman of Its National Advisory Board 3Health News:Ikaria(R) Acquires North American Rights to LUCASSIN(R) From Orphan Therapeutics 2Health News:Ikaria(R) Acquires North American Rights to LUCASSIN(R) From Orphan Therapeutics 3Health News:Sharon Callahan Joins Diversified Agency Services Unit of Omnicom Group 2Health News:Cholesterol Awareness Month: Americans Urged to Seek Early Intervention 2Health News:Breast Cancer Drug Not Tied to Cognitive Decline: Study 2
A conservative, cost effective alternative to total knee replacement for patients with osteoarthritis primarily confined to one compartment....
...
... The Maxim Knee employs titanium alloy ... an excellent fixation surface. Biomet's ArCom ... durable and proven bearing material. The ... full inter-changeability. Modular tibial components offer ...
... The Natural-Knee family is a ... with over 14 years of proven ... several innovative features including a proprietary ... fixation in active patients, a unique ...
Medicine Products: